For decades, the medical community has viewed glioblastoma—the most aggressive and lethal form of primary brain cancer—as a relentless mass of malignant cells. However, new research suggests the tumor is less of a solitary growth and more of a complex, parasitic ecosystem. A team of scientists in Canada has discovered that specific brain cells helping deadly cancer grow are being hijacked by the tumor to accelerate its spread, uncovering a vulnerability that could be targeted with a medication already available on the market.
The study, published in the journal Neuron, reveals that certain cells originally designed to protect the brain’s wiring are instead providing the infrastructure for cancer to thrive. By identifying the precise communication channel these cells use to support the tumor, researchers from McMaster University and The Hospital for Sick Children (SickKids) have found a way to disrupt the growth of the cancer in laboratory models.
This discovery is particularly urgent given the prognosis for glioblastoma patients. Currently considered incurable, the disease typically progresses rapidly, with survival often measured in months. Because the tumor infiltrates healthy brain tissue so aggressively, traditional surgery and chemotherapy often fail to prevent recurrence, leaving patients and clinicians with very few therapeutic options.
The Betrayal of the Oligodendrocyte
To understand how the cancer spreads, the research team looked beyond the tumor cells themselves and focused on the surrounding environment, known as the tumor microenvironment. They identified a specific type of glial cell called the oligodendrocyte as a key collaborator in the cancer’s progression.
Under normal physiological conditions, oligodendrocytes serve a vital role in the central nervous system: they create the myelin sheath, the insulating layer that wraps around nerve fibers to ensure electrical signals travel quickly, and efficiently. However, the study found that in the presence of glioblastoma, these cells undergo a functional shift.
Instead of maintaining the brain’s healthy architecture, these oligodendrocytes begin sending signals that strengthen the tumor cells, helping them survive and expand into healthy tissue. This interaction effectively turns a protective cell into a supportive pillar for the malignancy. When the researchers blocked this specific communication pathway in lab models, the growth of the tumor dropped significantly.
“Glioblastoma isn’t just a mass of cancer cells, it’s an ecosystem,” says Sheila Singh, co-senior author of the study and professor of surgery at McMaster University. “By decoding how these cells talk to each other, we’ve found a vulnerability that could be targeted with a drug that’s already on the market.”
Repurposing an HIV Medication for Brain Cancer
The most immediate clinical implication of the study is the identification of a potential treatment. The researchers discovered that the communication between the oligodendrocytes and the glioblastoma cells relies on a specific receptor called CCR5.
The CCR5 receptor is not new to pharmacology. This proves the primary target of Maraviroc, a drug already approved and widely used in the treatment of HIV. Maraviroc works by blocking the CCR5 receptor to prevent the virus from entering human immune cells. The Canadian team found that this same mechanism could potentially be used to “silence” the signals that oligodendrocytes send to glioblastoma tumors.
Repurposing existing drugs—a process known as drug repositioning—is a strategic advantage in oncology. Because Maraviroc has already undergone rigorous safety testing and regulatory approval for human use, the path to clinical trials for cancer could be significantly shorter than developing a new molecule from scratch.
Jason Moffat, co-senior author of the study and head of the Genetics & Genome Biology program at SickKids, noted that the discovery reveals a “far more dynamic” cellular ecosystem than previously understood. He stated that identifying this therapeutic target opens a promising path to speed up the delivery of new options for patients.
A Pattern of Developmental Hijacking
This discovery does not exist in a vacuum; it builds upon a broader theory that glioblastomas “trick” the brain by mimicking early developmental processes. In 2024, Singh and Moffat published work in Nature Medicine demonstrating that cancer cells exploit pathways normally used during fetal brain development to migrate through the brain.
By combining these findings, the researchers are painting a picture of a cancer that is an expert in biological mimicry. It doesn’t just grow; it recruits local cells and uses ancient developmental blueprints to navigate and colonize the organ. This shift in perspective—from treating a tumor as a lump to treating it as a communication network—is driving a new direction in neuro-oncology.
The research was a collaborative effort involving Kui Zhai, a research associate at McMaster, and Nick Mikolajewicz, a former postdoctoral fellow at SickKids. The work was supported by the Canadian Institutes for Health Research and the 2020 William Donald Nash Brain Tumour Research Fellowship.
Comparison of Traditional vs. Ecosystem-Based Treatment
| Feature | Traditional Approach | Ecosystem-Based Approach |
|---|---|---|
| Primary Target | The cancer cell mass | Communication between cells |
| Goal | Kill malignant cells (Cytotoxicity) | Disrupt support networks (Signaling) |
| Key Mechanism | Surgery, Radiation, Chemotherapy | Receptor blockade (e.g., CCR5) |
| Focus | Tumor shrinkage | Slowing infiltration and growth |
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients seeking treatment for glioblastoma should consult with a qualified oncologist or neurosurgeon regarding available therapies and clinical trials.
The next phase of this research will likely involve determining the efficacy of Maraviroc in more complex biological models and assessing how the drug penetrates the blood-brain barrier in glioblastoma patients. Researchers are now working toward defining the parameters for potential human clinical trials to see if blocking the CCR5 pathway can extend survival rates.
We invite readers to share this story and join the conversation in the comments below regarding the future of repurposed medications in cancer care.
Related reading
